Argatroban Solution
Product Images NDC 87188-104

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Argatroban (NDC 87188-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Plano Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vial Label (1)

Vial Label (1)
This is a description of an injectable medication called Argatroban Injection, containing 1 mg of argatroban and 9 mg of sorbitol in water for injection with 0.9% Sodium Chloride. It is packaged in a 125 mg/125 mL vial and should be stored between 20°C to 26°C (68°F-77°F) for intravenous use only. The medication should not be frozen and must be stored in its original carton. Distributed by B T e inks & 60005.*
FDA Label Image

Carton Label (2)

FDA Label Image

Argatroban-chemical-structure (Argatroban 01)

FDA Label Image

Figure-1 (Argatroban 02)

FDA Label Image

Figure-2 (Argatroban 03)

FDA Label Image

Figure-3 (Argatroban 04)

Figure-3 (Argatroban 04)
This text provides results from a study involving two groups: the Argatrgban group with 160 participants and the Historical Control group with 147 participants. The study involved monitoring for clinical endpoints such as death, amputation, or new thrombosis over a maximum follow-up period of 37 days. The text also includes a p-value of 0.007, suggesting a significant difference between the groups in relation to the clinical endpoints.*
FDA Label Image

Figure-4 (Argatroban 05)

Figure-4 (Argatroban 05)
This text provides data comparing Argatroban treatment (N = 144, censored = 8) with historical control (N = 46, censored = 20) in terms of event-free outcomes, with a calculated p value of 0.018. Censored cases indicate no clinical endpoint (death, amputation, or new thrombosis) was observed during the study period, which lasted up to 37 days.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.